Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
January 3, 2023
First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received Breakthrough Therapy Designation and a...
-
December 20, 2022
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system...
-
December 5, 2022
Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs Focused psychiatry practice expert in PTSD, Affective Disorders and Schizophrenia...
-
December 2, 2022
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it received written notice on December 1, 2022 from The...
-
November 14, 2022
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx Pharmaceuticals"), today announced that they have entered into...
Click here to view our corporate presentation or on the image below